Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Publications

Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Perspective and future direction of intraventricular mechanical dyssynchrony assessment.

PMID: 30684259
Journal: JOURNAL OF NUCLEAR CARDIOLOGY
Year: 2021
Reference: J Nucl Cardiol. 2021 Feb;28(1):65-71. doi: 10.1007/s12350-019-01604-3. Epub 2019 Jan 25.
Impact factor: 5.952
Publication type: Editorail in international publication
Authors: Romero-Farina, Guillermo, Aguade-Bruix, Santiago et al.
DOI: 10.1007/s12350-019-01604-3

Perspective and future direction of intraventricular mechanical dyssynchrony assessment.

PMID: 30684259
Journal: JOURNAL OF NUCLEAR CARDIOLOGY
Year: 2021
Reference: J Nucl Cardiol. 2021 Feb;28(1):65-71. doi: 10.1007/s12350-019-01604-3. Epub 2019 Jan 25.
Impact factor:
Publication type: Editorail in international publication
Authors: Aguade-Bruix, Santiago; Romero-Farina, Guillermo et al.
DOI: 10.1007/s12350-019-01604-3

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

PMID: NOPMID0090
Journal: Cancer Drug Resistance
Year: 2021
Reference: Cancer Drug Resistance. 2021;4(1):44-68.
Impact factor: 0
Publication type: Review in international publication
Authors: Ulldemolins, Anna, Seras-Franzoso, Joaquin, Andrade, Fernanda, Rafael, Diana, Abasolo, Ibane, Gener, Petra, Schwartz, Simo et al.
DOI: 10.20517/cdr.2020.59

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

PMID: NOPMID0090
Journal: Cancer Drug Resistance
Year: 2021
Reference: Cancer Drug Resistance. 2021;4(1):44-68.
Impact factor:
Publication type: Review in international publication
Authors: Abasolo, Ibane; Andrade, Fernanda; Gener, Petra; Rafael, Diana; Schwartz, Simo; Seras-Franzoso, Joaquin; Ulldemolins, Anna et al.
DOI: 10.20517/cdr.2020.59

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics.

PMID: 35582007
Journal: Cancer Drug Resistance
Year: 2021
Reference: Cancer Drug Resist. 2021 Mar 19;4(1):44-68. doi: 10.20517/cdr.2020.59. eCollection 2021.
Impact factor:
Publication type: Review in international publication
Authors: Abasolo, Ibane; Andrade, Fernanda; Gener, Petra; Rafael, Diana; Schwartz, Simo Jr; Seras-Franzoso, Joaquin; Ulldemolins, Anna et al.
DOI: 10.20517/cdr.2020.59

Pharmaceutical interventions in the emergency department: cost-effectiveness and cost-benefit analysis.

PMID: 35049519
Journal: European Journal of Hospital Pharmacy
Year: 2021
Reference: Eur J Hosp Pharm. 2021 May;28(3):133-138. doi: 10.1136/ejhpharm-2019-002067. Epub 2020 Feb 25.
Impact factor: 1.652
Publication type: Paper in international publication
Authors: Miarons, Marta, Marin, Sergio, Amenos, Imma, Campins, Lluis, Rovira, Montse, Daza, Manuel et al.
DOI: 10.1136/ejhpharm-2019-002067

Pharmaceutical interventions in the emergency department: cost-effectiveness and cost-benefit analysis.

PMID: 35049519
Journal: European Journal of Hospital Pharmacy
Year: 2021
Reference: Eur J Hosp Pharm. 2021 May;28(3):133-138. doi: 10.1136/ejhpharm-2019-002067. Epub 2020 Feb 25.
Impact factor:
Publication type: Paper in international publication
Authors: Amenos, Imma; Campins, Lluis; Daza, Manuel; Marin, Sergio; Miarons, Marta; Rovira, Montse et al.
DOI: 10.1136/ejhpharm-2019-002067

Pharmacogenetics of trough serum anti-TNF levels in pediatric inflammatory bowel disease.

PMID: 32478906
Journal: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Year: 2021
Reference: Br J Clin Pharmacol. 2021 Feb;87(2):447-457. doi: 10.1111/bcp.14400. Epub 2020 Jul 1.
Impact factor:
Publication type: Paper in international publication
Authors: Abarca-Zabalia, Judith; Alvarez-Vayo, Concepcion; Aznal, Elena; Balboa-Vega, Maria Jesus; Blanca-Garcia, Jose A; Bossacoma, Ferran; Clemente, Susana; de Caldas, Rafael Gonzalez; Eizaguirre, Francisco J; Gallego-Fernandez, Carmen et al.
DOI: 10.1111/bcp.14400

Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease.

PMID: 34603940
Journal: Current treatment options in rheumatology
Year: 2021
Reference: Curr Treatm Opt Rheumatol. 2021;7(4):319-333. doi: 10.1007/s40674-021-00186-x. Epub 2021 Sep 28.
Impact factor: 0
Publication type: Review in international publication
Authors: Sanchez-Pernaute, O, Pinal-Fernandez, I, Ruiz-Rodriguez, J C, Gil-Vila, A, Trallero-Araguas, E, Romero-Bueno, F, Selva-O'Callaghan, A et al.
DOI: 10.1007/s40674-021-00186-x

Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease.

PMID: 34603940
Journal: Current treatment options in rheumatology
Year: 2021
Reference: Curr Treatm Opt Rheumatol. 2021;7(4):319-333. doi: 10.1007/s40674-021-00186-x. Epub 2021 Sep 28.
Impact factor:
Publication type: Review in international publication
Authors: Gil-Vila, A; Pinal-Fernandez, I; Romero-Bueno, F; Ruiz-Rodriguez, J C; Sanchez-Pernaute, O; Selva-O'Callaghan, A; Trallero-Araguas, E et al.
DOI: 10.1007/s40674-021-00186-x

Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly.

PMID: 34664531
Journal: Expert Review of Clinical Pharmacology
Year: 2021
Reference: Expert Rev Clin Pharmacol. 2021 Dec;14(12):1551-1560. doi: 10.1080/17512433.2021.1986004. Epub 2021 Nov 8.
Impact factor:
Publication type: Paper in international publication
Authors: Badiu, Corin; Biagetti, Betina; Durand-Gasselin, Lucie; Neggers, Sebastian; Petit, Anne; Petrossians, Patrick; Regnault, Benjamin; Rich, David; Shafigullina, Zulfiya; Shustov, Sergey et al.
DOI: 10.1080/17512433.2021.1986004

Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.

PMID: 32915419
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2021
Reference: Invest New Drugs. 2021 Feb;39(1):193-201. doi: 10.1007/s10637-020-00944-z. Epub 2020 Sep 11.
Impact factor:
Publication type: Paper in international publication
Authors: Azaro, Analia; Baldini, Capucine; Benhadji, Karim A; Lithio, Andrew; Massard, Christophe; Oakley, Gerard; Rodon, Jordi; Soria, Jean-Charles; Yuen, Eunice et al.
DOI: 10.1007/s10637-020-00944-z

Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours.

PMID: 33941878
Journal: BRITISH JOURNAL OF CANCER
Year: 2021
Reference: Br J Cancer. 2021 Jul;125(1):28-37. doi: 10.1038/s41416-021-01389-8. Epub 2021 May 3.
Impact factor:
Publication type: Paper in international publication
Authors: Argiles, Guillem; Connolly, Roisin M; de Jonge, Maja; Dobson, Jason R; Garralda, Elena; Giannakis, Marios; Janku, Filip; Ji, Yan; McLaughlin, Margaret E; Moody, Susan E et al.
DOI: 10.1038/s41416-021-01389-8

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.

PMID: 33148674
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. Epub 2020 Nov 4.
Impact factor: 12.531
Publication type: Paper in international publication
Authors: Won, Helen H, Bond, John, Jones, Surai, Savage, Heidi M, Scaltriti, Maurizio, Wilson, Timothy R, Wei, Michael C, Hyman, David M, Dunn, Lara, Sachdev, Jasgit C et al.
DOI: 10.1158/1078-0432.CCR-20-2657

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.

PMID: 33148674
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. Epub 2020 Nov 4.
Impact factor:
Publication type: Paper in international publication
Authors: Aljumaily, Raid; Bedard, Philippe L; Bond, John; Chang, Matthew T; Dunn, Lara; Gambardella, Valentina; Hyman, David M; Jhaveri, Komal; Jones, Surai; Juric, Dejan et al.
DOI: 10.1158/1078-0432.CCR-20-2657

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.

PMID: 34385069
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2021
Reference: Eur J Cancer. 2021 Sep;155:168-178. doi: 10.1016/j.ejca.2021.05.040. Epub 2021 Aug 9.
Impact factor: 9.162
Publication type: Paper in international publication
Authors: Matos, Ignacio, Villacampa, Guillermo, Garralda, Elena, Dienstmann, Rodrigo, Tabernero, Josep, Felip, Enriqueta, Hierro, Cinta, Martin-Liberal, Juan, Berche, Roger, Pedrola, Anna et al.
DOI: 10.1016/j.ejca.2021.05.040

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.

PMID: 34385069
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2021
Reference: Eur J Cancer. 2021 Sep;155:168-178. doi: 10.1016/j.ejca.2021.05.040. Epub 2021 Aug 9.
Impact factor:
Publication type: Paper in international publication
Authors: Alonso, Guzman; Azaro, Analia; Berche, Roger; Brana, Irene; Carles, Joan; Dienstmann, Rodrigo; Elez, Elena; Felip, Enriqueta; Galvao, Vladimir; Gardeazabal, Itziar et al.
DOI: 10.1016/j.ejca.2021.05.040

Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.

PMID: 33046517
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12.
Impact factor: 12.531
Publication type: Paper in international publication
Authors: Di Martino, Jorge, Hollebecque, Antoine, Salvagni, Stefania, Plummer, Ruth, Isambert, Nicolas, Niccoli, Patricia, Capdevila, Jaume, Curigliano, Giuseppe, Moreno, Victor, Martin-Romano, Patricia et al.
DOI: 10.1158/1078-0432.CCR-20-2380

Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.

PMID: 33046517
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12.
Impact factor:
Publication type: Paper in international publication
Authors: Arias, Marina; Aronchik, Ida; Baudin, Eric; Capdevila, Jaume; Curigliano, Giuseppe; de Alvaro, Juan; de Bono, Johann S; Di Martino, Jorge; Filvaroff, Ellen H; Hollebecque, Antoine et al.
DOI: 10.1158/1078-0432.CCR-20-2380

Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and GM-CSF in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

PMID: 33942954
Journal: ONCOLOGIST
Year: 2021
Reference: Oncologist. 2021 Sep;26(9):e1508-e1513. doi: 10.1002/onco.13810. Epub 2021 May 22.
Impact factor:
Publication type: Paper in international publication
Authors: Babiker, Hani M; Brana, Irene; Calvo, Emiliano; Crittenden, Marka; Feng, Minjie; Formenti, Silvia; Fury, Matthew; Garrido, Pilar; Giralt, Jordi; Hervas-Moron, Asuncion et al.
DOI: 10.1002/onco.13810

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.

PMID: 33452559
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2021
Reference: Cancer Chemother Pharmacol. 2021 Apr;87(4):543-553. doi: 10.1007/s00280-020-04214-w. Epub 2021 Jan 15.
Impact factor: 3.333
Publication type: Paper in international publication
Authors: Lopez-Vivanco, Guillermo, Gonzalez Cebrian, Irene, Casado Gonzalez, Esther, Mondejar Solis, Rebeca, Feliu, Jaime, Jorge Fernandez, Monica, Macarulla, Teresa, Massuti, Bartomeu, Albero, Ana, Gonzalez Gonzalez, Jose Federico et al.
DOI: 10.1007/s00280-020-04214-w

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.

PMID: 33452559
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2021
Reference: Cancer Chemother Pharmacol. 2021 Apr;87(4):543-553. doi: 10.1007/s00280-020-04214-w. Epub 2021 Jan 15.
Impact factor:
Publication type: Paper in international publication
Authors: Albero, Ana; Casado Gonzalez, Esther; Delgado-Mingorance, Juan Ignacio; Feliu, Jaime; Fernandez Montes, Ana; Garcia Piernavieja, Carmen; Gonzalez Cebrian, Irene; Gonzalez Gonzalez, Jose Federico; Jorge Fernandez, Monica; Lopez Munoz, Ana Maria et al.
DOI: 10.1007/s00280-020-04214-w

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.

PMID: 34452745
Journal: GYNECOLOGIC ONCOLOGY
Year: 2021
Reference: Gynecol Oncol. 2021 Nov;163(2):274-280. doi: 10.1016/j.ygyno.2021.08.018. Epub 2021 Aug 25.
Impact factor: 5.482
Publication type: Paper in international publication
Authors: Oaknin, Ana, Monk, Bradley J, Selle, Frederic, Rojas, Carlos, Gladieff, Laurence, Berton, Dominique, Leary, Alexandra, Moore, Kathleen N, Estevez-Diz, Maria D P, Hardy-Bessard, Anne-Claire et al.
DOI: 10.1016/j.ygyno.2021.08.018

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.

PMID: 34452745
Journal: GYNECOLOGIC ONCOLOGY
Year: 2021
Reference: Gynecol Oncol. 2021 Nov;163(2):274-280. doi: 10.1016/j.ygyno.2021.08.018. Epub 2021 Aug 25.
Impact factor:
Publication type: Paper in international publication
Authors: Alexandre, Jerome; Ancukiewicz, Marek; Berton, Dominique; de Azevedo, Carla Rameri A S; Estevez-Diz, Maria D P; Feliu, Waldo Ortuzar; Gladieff, Laurence; Hardy-Bessard, Anne-Claire; Leary, Alexandra; Monk, Bradley J et al.
DOI: 10.1016/j.ygyno.2021.08.018